Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

CV Sciences, Inc. CVSI

15 fiscal years on record · USD · FY2025 reported · SEC filings only
$13.8M
▼ 12.2% YoY
$-958,000
$-516,000

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 13.8M
Revenue, FY2025 · full 15-year series below
Revenue $M Net income $M
FY2025 · Revenue 13.8 · Net income -1.0
20M40M-10M-20M
201120142017202020232025
Compound annual growth
−5.2%
−10.8%
+1.8%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at −10.8% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−7 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -3.4% · Net -6.9%
10%20%-50%-100%
201120182025
ROE
FY2025 · ROE -58.7%
20%40%-100%-200%
201120182025
Three returns, three denominators.
Gross margin49.0%
Operating margin-3.4%
Net margin-6.9%
EBITDAUSD -278,000.00

Each USD of equity lost 59 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -0.5
5M10M-3M-6M
201120182025

Total assetsUSD 7.0M
EquityUSD 1.5M
CashUSD 278,000.00
Gross debtUSD 1.6M
Net debtUSD 1.4M
Current ratio1.03×

Net debt stands at 93% of equity.

The 15-year record

15 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
CVSI, 15-year financial record
Metric 202520242023202220212020201920182017201620152014201320122011
Revenue $B0.00.00.00.00.00.00.10.00.00.00.00.00.00.0◌
Operating income $B−0.0−0.00.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0◌
EBITDA $B−0.0−0.00.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0◌◌◌
Income tax $B0.0−0.0−0.0−0.0−0.0−0.0−0.00.0−0.00.00.00.00.00.0◌
Net income $B−0.0−0.00.0−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.00.0−0.0−0.0−0.0−0.00.00.0−0.0−0.0−0.0−0.0−0.0◌
EPS, diluted $−0.01−0.010.02−0.07−0.14−0.22−0.170.09−0.06−0.27−0.35◌−0.23−0.01−0.01
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————
ROE %−58.7−101.9——−210.8−110.4−56.143.0−33.1−77.5−55.2−8.9———
Shares out B0.180.180.160.150.110.100.100.090.090.060.050.030.020.010.01

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 72 reconciliationsAUDITED

Reconciled in 15 of the 15 fiscal years we could check. 10 checks were skipped: the balance sheet is not tagged before 2012. Five checks were skipped: revenue is not tagged before 2012. Four checks were skipped: EPS is not tagged before 2011.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2011

Share this section

Download image